Viking Therapeutics, Inc. (VKTX)
26.86
+1.50
(+5.91%)
USD |
NASDAQ |
Oct 29, 16:00
26.50
-0.36
(-1.34%)
Pre-Market: 09:06
Viking Therapeutics Cash from Operations (Quarterly)
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -125.17M |
| March 31, 2026 | -113.98M |
| December 31, 2025 | -85.29M |
| September 30, 2025 | -94.00M |
| June 30, 2025 | -47.06M |
| March 31, 2025 | -52.33M |
| December 31, 2024 | -31.18M |
| September 30, 2024 | -21.96M |
| June 30, 2024 | -28.51M |
| March 31, 2024 | -6.134M |
| December 31, 2023 | -17.64M |
| September 30, 2023 | -19.66M |
| June 30, 2023 | -11.44M |
| March 31, 2023 | -24.64M |
| December 31, 2022 | -10.93M |
| September 30, 2022 | -13.50M |
| June 30, 2022 | -13.44M |
| March 31, 2022 | -10.53M |
| December 31, 2021 | -12.35M |
| September 30, 2021 | -10.93M |
| June 30, 2021 | -13.43M |
| March 31, 2021 | -10.88M |
| December 31, 2020 | -5.486M |
| September 30, 2020 | -5.323M |
| June 30, 2020 | -6.666M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.302M |
| December 31, 2019 | -11.74M |
| September 30, 2019 | -3.398M |
| June 30, 2019 | -6.459M |
| March 31, 2019 | -3.152M |
| December 31, 2018 | -2.679M |
| September 30, 2018 | -5.503M |
| June 30, 2018 | -5.27M |
| March 31, 2018 | -5.303M |
| December 31, 2017 | -3.948M |
| September 30, 2017 | -3.328M |
| June 30, 2017 | -4.203M |
| March 31, 2017 | -3.279M |
| December 31, 2016 | -2.465M |
| September 30, 2016 | -2.654M |
| June 30, 2016 | -3.227M |
| March 31, 2016 | -2.725M |
| December 31, 2015 | -3.299M |
| September 30, 2015 | -3.400M |
| June 30, 2015 | -1.621M |
| March 31, 2015 | -0.4109M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | -0.4374M |
| March 31, 2014 | -0.1008M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly & Co. | -- |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Compass Therapeutics, Inc. | -14.74M |
| Structure Therapeutics, Inc. | -120.38M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow Yield | -13.43% |